Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

denosumab Articles

Sales of cancer pain therapies set to grow to $5.2 billion in the G7 by 2021

13 December 2012

Denosumab reduces burden of giant-cell tumor of the bone

25 September 2012

Denosumab superior to zoledronic acid for breast cancer patients with bone metastases

15 August 2012

Daiichi Sankyo debuts bone cancer drug Ranmark in Japan

17 April 2012

Daiichi Sankyo files denosumab in Japan for osteoporosis

26 March 2012

Japanese approval for Regnite and Ranmark

18 January 2012

Backing for Japanese approval of Regnite, Ranmark and Cancidas

5 December 2011

In Japan, AstraZeneca to co-promote denosumab with Daiichi; Sosei debuts NorLevo

24 May 2011

US FDA approves expanded use of Amgen’s bone drug denosumab, which could boost potential sales to $2.4 billion

19 November 2010

Strong cancer drug results presented by Roche, Sanofi-Aventis, Merck KGaA, Amgen and Eisai at ESMO Congress

12 October 2010

FDA Grants priority review for Amgen’s denosumab BLA for the reduction of skeletal-related events in advanced cancer patients

19 July 2010

More good news for Amgen as denosumab shows promise in cancer patients

7 June 2010

Amgen files for second US approval of bone drug denosumab, aiming for cancer patient market; FDA backs rotavirus vaccines

17 May 2010

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Elan makes "transformational" acquisitions and a divestment
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Elan makes "transformational" acquisitions and a divestment

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS